Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

38.47 -1.30 (-3.27%)
Streaming Delayed Price Updated: 3:57 PM EDT, Aug 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 392,126
Open 39.89
Bid (Size) 38.45 (600)
Ask (Size) 38.48 (500)
Prev. Close 39.77
Today's Range 38.44 - 40.15
52wk Range 25.52 - 40.87
Shares Outstanding 57,031,297
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Harmony Biosciences (HRMY) Q2 2026 Earnings Call Transcript ↗
WAKIX revenue surged 30% to $261.3 million, confirming $1 billion annual guidance. 
Via The Motley Fool
Topics Earnings
News headline image
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
From Harmony Biosciences
Via GlobeNewswire

Performance

YTD
+2.9%
+2.9%
1 Month
+8.2%
+8.2%
3 Month
+24.8%
+24.8%
6 Month
+5.1%
+5.1%
1 Year
+8.5%
+8.5%

More News

Read More
News headline image
Harmony Biosciences Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
From Harmony Biosciences
Via GlobeNewswire
Harmony Biosciences Holdings (NASDAQ:HRMY): A Value Stock with Strong Financial Health ↗
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Q1 Revenue Meets Guidance, But EPS Miss and Elevated Spending Weigh on Shares ↗
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY): A Decent Value Play with Strong Fundamentals ↗
Via Chartmill
News headline image
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
From Harmony Biosciences
Via GlobeNewswire
News headline image
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony (HRMY) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Intellectual Property
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Case for Quality at a Discount ↗
Via Chartmill
News headline image
Harmony Biosciences to Participate in Upcoming Investor Conferences
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
A Healthcare Fund Just Made Bitgo Its Biggest Bet ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A beaten-down biotech just lost a meaningful backer — should you care? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
Via Finterra
Topics Economy Intellectual Property
News headline image
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
Via MarketMinute
News headline image
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
Via MarketMinute
Topics Intellectual Property
News headline image
Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference
From Harmony Biosciences Holdings, Inc.
Via Business Wire
News headline image
Harmony Biosciences to Participate in Upcoming Investor Conferences
From Harmony Biosciences Holdings, Inc.
Via Business Wire

Frequently Asked Questions

Is Harmony Biosciences Holdings, Inc. - Common Stock publicly traded?
Yes, Harmony Biosciences Holdings, Inc. - Common Stock is publicly traded.
What exchange does Harmony Biosciences Holdings, Inc. - Common Stock trade on?
Harmony Biosciences Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock?
The ticker symbol for Harmony Biosciences Holdings, Inc. - Common Stock is HRMY on the Nasdaq Stock Market
What is the current price of Harmony Biosciences Holdings, Inc. - Common Stock?
The current price of Harmony Biosciences Holdings, Inc. - Common Stock is 38.47
When was Harmony Biosciences Holdings, Inc. - Common Stock last traded?
The last trade of Harmony Biosciences Holdings, Inc. - Common Stock was at 08/13/26 03:57 PM ET
What is the market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock?
The market capitalization of Harmony Biosciences Holdings, Inc. - Common Stock is 2.19B
How many shares of Harmony Biosciences Holdings, Inc. - Common Stock are outstanding?
Harmony Biosciences Holdings, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.